An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)

Completed · Phase 3 · Has a placebo group

Conditions studied: Critical Limb Ischemia

In brief

This study is designed to evaluate the efficacy and safety of ixmyelocel-T, a patient-specific expanded multicellular therapy, for the treatment of patients with critical limb ischemia (CLI). The study is a randomized, vehicle controlled (placebo)study in CLI patients who have no option for revascularization procedures. All patients randomized will undergo a small volume bone marrow aspiration in a 15-minute outpatient or in-office procedure. All patients will receive injections of either ixmyelocel-T or vehicle-control into their pre-identified index leg. Patients will be followed for 18 months.

Key facts

Study ID: NCT01483898
Run by: Vericel Corporation
People needed: 41
Starts: 2012-02-01
Expected to finish: 2014-03-25
Last updated by the study team: 2021-05-27

Who can join

Age: 35 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Males and nonpregnant, nonlactating females
Ages 35 to 90 years of age
Diagnosis of CLI with tissue loss (corresponding to Rutherford Category 5; see Appendix B) having an ulcer size of at least 0.5 cm2, a smaller sized ulcer penetrating into the subcutaneous tissue, and/or gangrene (dry). In addition, the subject must have ONE of the following documented at screening:
Ankle systolic pressure < 70 mm Hg
Toe systolic pressure < 50 mm Hg
TcPO2 < 30 mm Hg (in a supine position)
Subjects must have no reasonable standard-of-care options for surgical or endovascular revascularization interventions
Subjects must have the following:
A narrative documenting the reasons why the site vascular specialist considers the subject "no option". A vascular specialist will be the principal investigator (PI) or subinvestigator and is defined as: vascular surgeon, interventional cardiologist, certified vascular medicine specialist, or interventional radiologist; AND
Secondary confirmation by an independent Eligibility Review Committee (ERC; see Section 8.1) after review of appropriate documents including, but not limited to: imaging results, medical records, surgical history, site vascular specialist narrative documenting reasons for "no option," and/or lab reports.
Major amputation in the index leg or death is not anticipated within 3 months of screening in the opinion of the vascular specialist (who must be the PI or subinvestigator)
In the opinion of the investigator, the subject is controlled on medical therapy indicated for CLI (unless there is a documented contraindication or intolerance)
Subject is current with all age-appropriate American Cancer Society (ACS) or similar (e.g., United States Preventative Service Task Force) screening guidelines
Given medical history and concurrent medication, the subject is an acceptable candidate for bone marrow aspiration and intramuscular injection procedures in the opinion of the Investigator
Subject is willing and able to comply with the scheduled visits, aspiration/injection procedure, wound care instructions treatment plan, and other study procedures for the duration of the study
Provide a personally-signed and dated informed consent document indicating that the subject (or a legally-acceptable representative, if permitted by the site's Investigational Review Board [IRB]) has been informed of all pertinent aspects of the study

You may not qualify if…

Patients presenting with any of the following will not be randomized:
Disease-specific:
Failed open surgical revascularization (on index leg) within 4 weeks of screening Visit 1
Acute limb-threatening ischemia, trauma, known non-atherosclerotic vascular disease (e.g., temporal/giant cell arteritis, Takayasu's arteritis, Raynaud's occlusive disease, Buerger's disease), embolic disease, aortoiliac disease with > 50% stenosis, or history of hypercoagulable states
Advanced CLI (i.e., nonsalvageable) defined as Rutherford Category 6
Clinical evidence of invasive infection in index leg (e.g., cellulitis, osteomyelitis, wet gangrene)
At screening, non-heel wound size of > 20 cm2 (excluding toe gangrene); or wounds on the heel > 10 cm2 on the index leg as measured by the Wound Core Lab (WCL) from photographs (and/or acetates) provided by the site
Previous amputation at or above the talus in the index leg Medical History
Hemoglobin A1c (HbA1c) ≥ 10% at screening
Diabetic subjects with uncontrolled or untreated proliferative retinopathy as determined by dilated eye exam (by qualified eye care professional as per American Diabetes Association guidelines)
Blood clotting disorder not caused by medication (e.g., thrombophilia)
Active non-basal cell cutaneous malignancy requiring surgery, chemotherapy, and/or radiation in the past 12 months
Current documented drug or alcohol abuse that would interfere with the subject's compliance with study procedures
Known allergies to any equine, porcine, or bovine products
Body mass index (BMI) ≥ 50 kg/m2 at screening
Established chronic kidney disease (CKD) requiring dialysis (Stage 5); estimated creatinine clearance < 15 mg/mL/min at screening
Systolic blood pressure (SBP) > 200 mm Hg or diastolic blood pressure (DBP) > 120 mm Hg or papilledema noted via ophthalmoscope at screening physical exam
Within 3 months prior to screening, a clinically significant history of cardiac disease
Laboratory Parameters:
Abnormal laboratory values (performed at central lab) at screening:
Platelets < 50,000 μL
Aspartate aminotransferase/alanine aminotransferase (AST/ALT) > 3 times the upper limit of normal (ULN)
Human immunodeficiency virus 1 (HIV 1), HIV 2, or syphilis positive (rapid plasma reagin [RPR])
Active hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV); Exclusionary Procedures, Devices, or Medication
Exposure to immunosuppressive therapy for oncologic or chronic non-oncologic reasons in the prior 12 months or expected requirement over the course of the study (e.g., chemotherapy, radiation therapy, methotrexate)

Where it is running

Cardio-Thoracic Surgeons, P.C. — Birmingham, Alabama, United States
University Of Alabama At Birmingham — Birmingham, Alabama, United States
Arizona Heart Institute — Phoenix, Arizona, United States
Carl T. Hayden VA Medical Center — Phoenix, Arizona, United States
University of Arizona — Tucson, Arizona, United States
Arkansas Primary Care Clinic, P.A. — Little Rock, Arkansas, United States
Central Arkansas Veteran's Healthcare System — Little Rock, Arkansas, United States
John Muir Medical Center - Concord Campus — Concord, California, United States
VA Loma Linda Healthcare — Loma Linda, California, United States
UCLA Gonda Venous Center & Ambulatory Procedure Unit — Los Angeles, California, United States
Sutter Medical Group - Cardiology — Sacramento, California, United States
University of California San Diego Medical Center — San Diego, California, United States
Kaiser Permanente Medical Center — San Diego, California, United States
University of California San Francisco - Division of Vascular and Endovascular Surgery — San Francisco, California, United States
University of Colorado Denver - Anschutz Medical Campus — Aurora, Colorado, United States
Yale School of Medicine — New Haven, Connecticut, United States
Bethesda Memorial Hospital - Clinical Research Center — Boynton Beach, Florida, United States
Holy Cross Hospital — Fort Lauderdale, Florida, United States
Florida Research Network, LLC — Gainesville, Florida, United States
Malcom Randall Veterans Affairs Medical Center — Gainesville, Florida, United States
First Coast Cardiovascular Institute, P.A. — Jacksonville, Florida, United States
University of Miami Hospital — Miami, Florida, United States
Orlando Health — Orlando, Florida, United States
Baptist Hospital — Pensacola, Florida, United States
Cardiology PC — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.